Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT - Free Report) in a research note published on Friday,Benzinga reports. They currently have a $63.00 price target on the biotechnology company's stock.

A number of other equities analysts have also weighed in on ARCT. Leerink Partnrs raised Arcturus Therapeutics to a "strong-buy" rating in a research report on Monday, August 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Finally, Leerink Partners initiated coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They set an "outperform" rating and a $70.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Arcturus Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $71.40.

Arcturus Therapeutics Trading Up 4.6 %

ARCT stock traded up $0.86 during mid-day trading on Friday, hitting $19.60. 315,465 shares of the company were exchanged, compared to its average volume of 466,657. The stock has a market capitalization of $527.83 million, a PE ratio of -7.65 and a beta of 2.64. Arcturus Therapeutics has a 1-year low of $17.26 and a 1-year high of $45.00. The business has a 50 day simple moving average of $20.64 and a 200-day simple moving average of $24.31.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The firm had revenue of $49.86 million for the quarter, compared to analysts' expectations of $21.00 million. During the same period in the prior year, the business earned ($1.98) EPS. Equities research analysts expect that Arcturus Therapeutics will post -2.6 earnings per share for the current year.

Insider Activity

In other news, COO Pad Chivukula sold 12,000 shares of the business's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares of the company's stock, valued at approximately $9,037,533.84. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 15.30% of the company's stock.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors have recently modified their holdings of the company. Quest Partners LLC lifted its holdings in Arcturus Therapeutics by 437.1% in the 3rd quarter. Quest Partners LLC now owns 19,810 shares of the biotechnology company's stock worth $460,000 after buying an additional 16,122 shares during the period. Royce & Associates LP lifted its position in shares of Arcturus Therapeutics by 18.3% in the 3rd quarter. Royce & Associates LP now owns 155,803 shares of the biotechnology company's stock worth $3,616,000 after purchasing an additional 24,085 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Arcturus Therapeutics by 45.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company's stock valued at $52,819,000 after purchasing an additional 712,650 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Arcturus Therapeutics in the third quarter worth about $544,000. Finally, ARK Investment Management LLC lifted its stake in shares of Arcturus Therapeutics by 6.9% in the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company's stock valued at $48,765,000 after purchasing an additional 136,074 shares during the period. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.